Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus
Objective Hydroxychloroquine (HCQ) is a mainstay of therapy in the treatment of SLE. The effect of HCQ on platelets and vascular health is uncertain. We investigated the relationship between HCQ use and dose with platelet activity, platelet transcriptomics and vascular health in patients with SLE.Me...
Saved in:
| Main Authors: | Peter Izmirly, H Michael Belmont, Jill P Buyon, MacIntosh Grant Cornwell, Elliot S Luttrell-Williams, Michael Golpanian, Hanane El Bannoudi, Khrystyna Myndzar, Stuart Katz, Nathaniel R Smilowitz, Alexis Engel, Robert Clancy, Kelly Ruggles, Jeffrey S Berger |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-04-01
|
| Series: | Lupus Science and Medicine |
| Online Access: | https://lupus.bmj.com/content/8/1/e000475.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
SLE: reconciling heterogeneity
by: Peter Izmirly, et al.
Published: (2019-12-01) -
Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program
by: Ellen Ginzler, et al.
Published: (2019-12-01) -
Hydroxychloroquine in patients with systemic lupus erythematosus: how much is enough?
by: Guillermo Ruiz-Irastorza, et al.
Published: (2025-04-01) -
Gut dysbiosis and the clinical spectrum in anti-Ro positive mothers of children with neonatal lupus
by: Robert M. Clancy, et al.
Published: (2022-12-01) -
Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus
by: Alberto Floris, et al.
Published: (2018-01-01)